Treatment with tolebrutinib delayed the time to onset of 6-month CDP by 31% compared with placebo. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib ...
NEW YORK (AP) — Alexion Pharmaceuticals Inc. said Tuesday that regulators have designated its experimental drug asfotase alfa as a breakthrough therapy for a rare metabolic disease that can cause ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results